Recent Company News

• 05:57 PM ET Jun 13, 2025
  

  FDA grants orphan drug designation to deramiocel for Becker muscular dystrophy ($11.78, 0.00)

• 10:52 PM ET May 06, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 06:21 PM ET Jun 10, 2025
  

  Nippon Shinyaku upgraded to buy from neutral at UBS (¥3545.0000, 0)

• 07:07 AM ET May 13, 2025
  

  REGENXBIO announces FDA acceptance and Priority Review of the BLA for RGX-121 for Mucopolysaccharidosis II (MPS II), also known as Hunter syndrome ($7.97, 0.00)

• 11:06 PM ET May 07, 2025
  

  Nippon Shinyaku reports FY net income attributable ¥32.56B vs FactSet ¥31.69B [7 est, ¥30.15-32.40B] (¥3461.0000, -23)

• 12:04 AM ET May 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 08:03 AM ET May 05, 2025
  

  Capricor Therapeutics announces completion of mid-cycle review meeting with FDA on Deramiocel in DMD; remains on track for 31-Aug-25 PDUFA ($11.86, 0.00)

• 09:07 AM ET Apr 21, 2025
  

  NS Pharma issues press release discussing previously reported orphan designation for NS-229 in treatment of Eosinophilic Granulomatosis with Polyangiitis (¥3570.0000, 0)